Cell Death and Differentiation Submission Process

The submission process is smoother when four questions are already answered.

If those answers are weak, the process will not hide them. It will expose them during the Initial Quality Check, editor assignment, or reviewer selection.

Prepare the package before starting the online form. Nature MTS is manageable when the files are stable and slow when the manuscript is still being assembled.

You should have:

• manuscript file with title page, unstructured abstract, main text, references, figure legends, acknowledgements, and declarations aligned
• title page with a brief title, running title, author names, affiliations, and corresponding-author email
• cover letter that explains the importance of the work, why it fits CDD's diverse readership, originality, competing interests, and any previous review history when relevant
• separate figure files with readable panels and consistent labels
• supplementary information and source data files, especially source data for tumour-growth figures where applicable
• competing-interest, funding, author-contribution, and data-availability statements
• ethics approval language for live vertebrate or higher-invertebrate experiments, human tissue, patient-derived materials, or clinical samples
• tumour-size or tumour-burden statement when the manuscript reports live-animal tumour experiments
• suggested independent reviewers and any opposed reviewers with clear justification

This is not just administration. A missing ethics sentence or vague data-availability statement can slow the process before the editor reaches the scientific claim. A generic cover letter can also weaken the first editorial read because the editor must reconstruct why the work belongs in Cell Death and Differentiation rather than Cell Death & Disease, Cell Death Discovery, Oncogene, Molecular Cell, Cell Reports, or a specialist apoptosis venue.

Cell Death and Differentiation submissions go through the journal's online manuscript tracking system at https://mts-cdd.nature.com. During upload, the corresponding author enters metadata, article type, author details, files, declarations, suggested reviewers, and cover-letter information.

The portal URL matters because it fixes the workflow shape. Nature's editorial-process page says the submitted manuscript receives a tracking number, then the editorial office performs an Initial Quality Check before editor handling. In practical terms, the upload becomes an editor-readable package, not just a file transfer. In our CDD process reviews, the upload fields often reveal whether the manuscript is controlled before the science is judged: article type, title-page consistency, ethics language, source-data readiness, reviewer suggestions, and whether the cover letter makes the mechanism obvious.

The practical upload sequence is:

1. create or enter the Nature manuscript tracking account
2. choose the article type, usually Article, Review Article, Perspective, Comment, Editorial, or Meeting Report depending on fit
3. enter title, abstract, authors, affiliations, corresponding-author details, and manuscript metadata
4. upload manuscript, figures, supplementary information, source data, and cover letter
5. complete competing-interest, funding, ethics, data availability, and other policy fields
6. add suggested reviewers and opposed reviewers with conflict-aware reasoning
7. review the generated submission package before final submission

Do not skip the generated-package check. Figure order, missing legends, broken symbols, author-order mistakes, omitted source data, or inconsistent ethics language are easiest to catch before the manuscript becomes a tracked editorial file.

Use these as planning ranges, not promises. CDD does not publish a guaranteed first-decision clock for every manuscript. The official process does state that reviewers are given 14 days from acceptance to submit reports, but reviewer invitation and acceptance can take time. For manuscripts that clear the editor's first screen, expect a first decision in about 4 to 8 weeks, with complex reviewer searches sometimes extending the first decision toward 8 to 14 weeks.

The calibrated range is therefore: administrative issues can surface in the first few days, editorial decisions without review can arrive in the first 1 to 3 weeks, externally reviewed papers often need 4 to 8 weeks for a first decision, and hard reviewer searches or additional reviewers can push the reviewed decision toward 8 to 14 weeks. If the paper is quiet after a month, that does not automatically mean rejection; it often means reviewer recruitment or report waiting.

The journal-specific process feature to remember is CDD Press transfer routing. If the editors decide the manuscript does not fit Cell Death and Differentiation, they may recommend transfer to Cell Death & Disease or Cell Death Discovery. Treat that as a fit signal, not an automatic downgrade. Accept the transfer only if the suggested journal owns the actual manuscript center: disease breadth, soundness-led discovery, translational framing, or basic cell-death mechanism.

After submission, the editorial office checks whether the package is complete and formatted correctly. This is not the scientific review, but it can delay the manuscript and weaken first impressions.

Common intake delays:

• cover letter does not include corresponding-author contact information, originality confirmation, or a clear journal-fit explanation
• competing-interest statement is missing from the manuscript or cover letter
• ethics approval language is too vague for animal or human-material work
• tumour-size or tumour-burden statements are missing for live-animal tumour experiments
• data availability is generic when datasets, source data, or repository links should be available
• source data for tumour-growth figures are missing or hard to match to figures
• figure files are low resolution, mislabeled, or inconsistent with legends
• author metadata differs between the title page and portal fields
• suggested reviewers have obvious conflicts or all come from one narrow subfield

Fix these before upload. Administrative returns are not fatal, but they make the process slower and signal that the package was not fully controlled.

Once the package is administratively complete, it moves to editorial handling. Nature's process says an Editor decides whether to send the manuscript to review and that papers judged insufficiently interesting or inappropriate are rejected promptly without external review.

The editor usually reads the title, abstract, cover letter, first figures, and scope signals first. The question is not "does this mention apoptosis, necroptosis, autophagy, ferroptosis, or differentiation?" It is "does this manuscript make a substantial, novel, mechanistic contribution for the CDD readership?"

Strong process signals:

• the abstract states the cell-death or differentiation mechanism causally
• the first figures show functional evidence, not only marker movement
• perturbation, rescue, genetic, in-vivo, or orthogonal validation supports the central claim
• the cover letter explains why CDD's diverse readership should care
• ethics, source data, and data availability can survive reviewer scrutiny

Weak process signals:

• the manuscript uses a cell-death label but the evidence is descriptive
• one reagent or one cell line carries the mechanistic conclusion
• in-vivo or genetic evidence confirms relevance but does not test mechanism
• disease context overwhelms the basic cell-death contribution
• the cover letter argues novelty or prestige rather than CDD-specific fit

This is why the submission-process page is separate from the submission-guide page. The guide helps decide whether the manuscript should target CDD. The process page explains what happens once that target choice becomes an uploaded file.

Cell Death and Differentiation triage is a mechanism, general-interest, and evidence-strength screen. Manuscripts that look descriptive, under-validated, or better suited to a CDD Press sibling journal can leave the process before peer review.

Methodology note: this page was created from official Nature and Springer Nature source checks, sibling-page overlap checks, and Manusights submission analysis of cell-death and molecular-cell-biology manuscripts. In our analysis of CDD submission packages, the fastest process failures are visible before peer review. We evaluate the same components an editor sees early: title, abstract, cover letter, first figure, validation figure, source data, ethics/data package, and suggested-reviewer field. The strongest CDD packages make the causal cell-death mechanism visible before the editor reaches the methods.

Cell-death marker movement without causal mechanism. This specific failure pattern is the fastest way for a CDD process to end early. Cleaved caspase staining, LC3 markers, viability changes, TUNEL signal, pathway enrichment, or stress markers can support a story, but they rarely prove the death program alone. Editors actually look for perturbation, rescue, time-course logic, and mode-of-death specificity before they spend reviewer capacity.

Check whether your CDD abstract reads as mechanism or marker description →.

Functional validation is too narrow for the claim. One knockdown, inhibitor, reporter, or cell line is vulnerable when the conclusion claims a pathway, death mode, differentiation program, or disease mechanism. A stronger package uses orthogonal perturbation, rescue, genetic support, time-course structure, and model choice that matches the claim. Manusights treats this as a submission-process issue because it changes whether an editor recruits reviewers or returns the paper before review.

Check whether your CDD validation package is broad enough →.

CDD Press routing is not resolved. A manuscript can be good science and still be a better Cell Death & Disease or Cell Death Discovery paper. If the manuscript center is disease association, translational observation, or soundness-led discovery rather than a mechanistic cell-death or differentiation contribution, the Cell Death and Differentiation process can end with rejection or transfer.

Check whether your CDD fit argument matches the evidence →.

Policy details expose an unfinished package. CDD's official guide names cover-letter, competing-interest, data/materials availability, ethics, tumour-size, and source-data details that can matter before review. When those fields are vague, the manuscript looks less controlled even if the science is promising.

Our analysis of CDD submission packages treats triage as a document-level test. The manuscript component that fails first is usually visible before peer review: abstract claim, first figure, validation breadth, source-data readiness, ethics language, or target-journal premise.

The practical pattern is specific to Cell Death and Differentiation. A paper can have real cell-death data and still enter the process weakly if the first screen sees markers before mechanism. We look for whether the abstract names the causal program, the first figure makes the biological problem visible, the second or third figure tests mechanism, and the validation evidence is not hidden late in supplementary data.

We also inspect the cover letter for a journal-specific sentence: why this manuscript belongs in Cell Death and Differentiation rather than Cell Death & Disease, Cell Death Discovery, Molecular Cell, Cell Reports, Oncogene, Autophagy, Apoptosis, Nature Cell Biology, or a disease-specialist journal. If that sentence is vague, the process becomes slower because the editor has to reconstruct the target fit.

The reviewer-count expectation is practical. If the manuscript goes out, expect at least one independent reviewer and often two or more, with reviewer roles split across cell-death mechanism, model system, disease context, imaging, omics, statistics, or in-vivo evidence. The review tells you whether your paper passes the same process screen editors look for before reviewer invitation. A paid Manusights review applies that same division before submission: mechanism, validation, journal fit, and reviewer-risk checks. Paid reviews include the 60-day money-back guarantee, and Manusights does not train models on submitted manuscripts. We do not train on submitted manuscripts.

If the manuscript clears triage, it can be assigned to a Receiving Editor who selects peer reviewers. The official peer-review terminology page describes the journal as single-blind in practical author terms: reviewers are not identified to authors unless a referee requests disclosure, and the terminology table calls the identity model single anonymized. The official process says reviewers are given 14 days from acceptance to submit reports. The time before acceptance can still vary because reviewer availability depends on topic, conflicts, method mix, and whether the manuscript's contribution is clear.

Reviewer assignment can slow when:

• the topic crosses cell-death biology, oncology, immunology, neuroscience, metabolism, and a specialist method
• suggested reviewers are too close to the authors
• the paper needs both mechanism review and disease-model review
• omics, imaging, animal, or clinical-sample claims need separate expertise
• the cover letter does not clarify the central contribution

Once reviewers agree, they usually test the same issues the editor screened for: mechanism, novelty, conceptual advance, source data, model choice, statistics, ethics, reproducibility, and whether the claim is proportionate.

The first decision after review is usually not a clean accept. For a promising CDD manuscript, expect major revision or detailed feedback around mechanism, controls, data transparency, and claim strength.

The best revision responses do not merely answer reviewer comments. They show that the manuscript now supports the cell-death or differentiation claim more directly than the submitted version did.

Do not interpret every quiet week as bad news. The stronger signal is which phase the manuscript is likely in. Early quiet often means editor triage or reviewer recruitment. Later quiet usually means reports or decision synthesis.

Submit to Cell Death and Differentiation when:

• the article is clearly centered on cell-death or differentiation biology
• the abstract states the mechanism causally
• functional validation supports the central claim
• in-vivo, genetic, rescue, time-course, orthogonal, or source-data support matches the level of claim
• the cover letter explains why CDD's diverse readership should care
• ethics, tumour-size, source-data, competing-interest, funding, author-contribution, and data-availability statements are complete
• the generated submission package looks exactly like the package you want editors and reviewers to read